BeiGene (NASDAQ:BGNE) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of BeiGene (NASDAQ:BGNE) in a research note released on Tuesday. The firm issued a hold rating on the stock.

Several other equities analysts also recently weighed in on BGNE. Morgan Stanley reiterated an “overweight” rating and issued a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. JPMorgan Chase & Co. lifted their target price on shares of BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a report on Tuesday, October 22nd. Finally, TD Cowen lifted their target price on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $253.69.

BeiGene Price Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. BeiGene has a 1 year low of $126.97 and a 1 year high of $248.16. The company has a market capitalization of $18.03 billion, a PE ratio of -22.42 and a beta of 0.57. The company’s fifty day moving average price is $194.32 and its two-hundred day moving average price is $188.98.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm’s revenue was up 28.2% compared to the same quarter last year. During the same period last year, the company earned $2.01 earnings per share. As a group, equities research analysts expect that BeiGene will post -5.64 EPS for the current year.

Insiders Place Their Bets

In related news, insider Xiaodong Wang sold 40,468 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker sold 1,037,017 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $187.27, for a total value of $194,202,173.59. Following the completion of the sale, the director now directly owns 791,493 shares in the company, valued at approximately $148,222,894.11. The trade was a 56.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,119,245 shares of company stock worth $209,700,084. 7.43% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BeiGene

Several hedge funds have recently modified their holdings of the stock. Blue Trust Inc. increased its holdings in shares of BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock valued at $28,000 after acquiring an additional 75 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in BeiGene during the 3rd quarter valued at approximately $36,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in BeiGene during the 3rd quarter valued at approximately $67,000. SG Americas Securities LLC acquired a new position in BeiGene during the 3rd quarter valued at approximately $105,000. Finally, PFG Investments LLC acquired a new position in BeiGene during the 3rd quarter valued at about $210,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.